E-DRUG: Independent Drug & Healthcare Newsletter for June 2016
-------------------------------------------------------------------------------------
Newsletter, June 2016
If your friends or colleagues would be interested, forward this email and invite them to sign up for the free Newsletter.
N° 172 June 2016
View the table of contents for the current issue
Subscribe to Prescrire International
In Prescrire's Spotlight this month
Empagliflozin (Jardiance°) in type 2 diabetes: no rush to use this drug
FEATURED REVIEW There is no evidence that empagliflozin has a favourable harm-benefit balance when used for prevention of the cardiovascular complications of type 2 diabetes. More trial data are needed on the harm-benefit balance of empagliflozin compared to other cardiovascular therapies.
Full review (3 pages) available for download by subscribers.
Read more
In the June issue of Prescrire International: decongestants during pregnancy - risks for the unborn child
FREE DOWNLOAD Sympathomimetic decongestants provoke serious, albeit rare, adverse effects. In the second and third trimesters of pregnancy, the fetus is exposed to the same adverse effects as the mother. These drugs should quite simply never be used, including via the nasal route.
Full text available for free download.
Read more
Prescrire: 100% financed by subcribers
Prescrire, financed solely through subscriptions, with no revenues from advertising or grants, publishes its accounts each year.
Read more
2015 drug packaging review: drug companies and insufficient regulation are putting patients at risk
Pharmaceutical companies are fully aware of the solutions for ensuring the quality and safety of drug packaging. But too much drug packaging remains unsafe and too many package leaflets are inadequate.
Read more
The drug pricing racket
The extortionate prices of some new drugs supposedly reflect their "value" for patients and for society. This argument does not hold water.
Read more
Remembering Andrew Herxheimer
A long-time friend and colleague and a source of inspiration for Prescrire, Andrew Herxheimer passed away on 21 February 2016 at the age of 90. Prescrire was greatly enriched by Andrew's ideas, vision, enthusiasm and experience.
Read more
Share this with a friend or colleague: Forward this email
Get this from a friend? Sign up here
"Prescrire International" <international@prescrire.org>